CytomX Therapeutics Inc
For the period ended Dec 31, 2024. Filed Mar 6, 2025.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2024 · Filed Mar 6, 2025
CTMX$1.980.0%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Statements of Operations and Comprehensive Income (Loss)
| Year Ended December 31, | ||
|---|---|---|
| 2024 | 2023 | |
| Revenues | $138,103 | $101,214 |
| Operating expenses: | ||
| Research and development | 83,382 | 77,680 |
| General and administrative | 29,726 | 30,018 |
| Total operating expenses | 113,108 | 107,698 |
| Income (loss) from operations | 24,995 | (6,484) |
| Interest income | 7,136 | 9,837 |
| Other income (expense), net | (38) | (30) |
| Income before income taxes | 32,093 | 3,323 |
| Provision for income taxes | 224 | 3,892 |
| Net income (loss) | 31,869 | (569) |
| Other comprehensive income (loss): | ||
| Unrealized gain (loss) on available-for-sale investments, net of tax | (68) | 85 |
| Total comprehensive income (loss) | $31,801 | $(484) |
| Net income (loss) per share: | ||
| Basic | $0.38 | $(0.01) |
| Diluted | $0.38 | $(0.01) |
| Shares used to compute net income (loss) per share | ||
| Basic | 84,439,303 | 73,808,237 |
| Diluted | 84,745,116 | 73,808,237 |
CYTOMX THERAPEUTIC, INC.
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.